Novartis U.S. Sales Force Increase Anticipates Up To Five NME Launches
Executive Summary
Novartis is ramping up its U.S. sales force in anticipation of a spate of product launches, the company indicated at its 1999 sales and earnings presentation in London Feb. 17.
You may also be interested in...
Novartis STI 571 Leukemia Trials Heading Toward NDA Filing At End Of 2001
Product registration trials for Novartis' STI 571 for chronic myelogenous leukemia began at the end of 1999, and an NDA filing for the product is planned within the next 18 months.
Novartis STI 571 Leukemia Trials Heading Toward NDA Filing At End Of 2001
Product registration trials for Novartis' STI 571 for chronic myelogenous leukemia began at the end of 1999, and an NDA filing for the product is planned within the next 18 months.
Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics
Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.